When Nationwide Children’s Hospital opens a commercial-scale manufacturing facility for gene therapies in three to four years, its impact could be felt far beyond the walls of the pediatric hospital.
Andelyn Biosciences Inc. could make Columbus a center for biomedical innovation listed in the same breath as Boston, Philadelphia and Research Triangle Park, said Dr. Dennis Durbin, chief scientific officer of the hospital’s Wexner Research Institute.
Click here to read the complete article.
Story excerpt provided by Columbus Business First.
Written by Carrie Ghose.
Originally published January 30, 2020.